Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer
BJ Solomon, CC Zhou, A Drilon, K Park, J Wolf… - Future …, 2021 - Taylor & Francis
Selpercatinib, a novel, highly selective and potent, inhibitor of RET, demonstrated clinically
meaningful antitumor activity with manageable toxicity in heavily pretreated and treatment …
meaningful antitumor activity with manageable toxicity in heavily pretreated and treatment …
Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial
PURPOSE Selpercatinib, a first-in-class, highly selective, and potent CNS-active RET kinase
inhibitor, is currently approved for the treatment of patients with RET fusion–positive non …
inhibitor, is currently approved for the treatment of patients with RET fusion–positive non …
Updated overall efficacy and safety of selpercatinib in patients (pts) with RET fusion+ non-small cell lung cancer (NSCLC).
9065 Background: Selpercatinib, a first-in-class highly selective and potent, CNS-active RET
kinase inhibitor, is approved in multiple countries for treatment of RET fusion+ lung or thyroid …
kinase inhibitor, is approved in multiple countries for treatment of RET fusion+ lung or thyroid …
27P Durability of efficacy and safety with selpercatinib in patients (pts) with RET fusion+ non-small cell lung cancer (NSCLC)
Background Selpercatinib, a first-in-class highly selective and potent CNS-active RET
kinase inhibitor, is approved in multiple countries for treatment of RET fusion+ NSCLC. In …
kinase inhibitor, is approved in multiple countries for treatment of RET fusion+ NSCLC. In …
Efficacy and safety of selpercatinib in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer: a phase II clinical trial (LIBRETTO-321)
S Lu, Y Cheng, D Huang, Y Sun, L Wu… - Therapeutic …, 2022 - journals.sagepub.com
Introduction: Oncogenic alterations in RET occur in 1–2% of non-small-cell lung cancers
(NSCLCs). The efficacy and safety of the first-in-class, highly selective, and potent RET …
(NSCLCs). The efficacy and safety of the first-in-class, highly selective, and potent RET …
[HTML][HTML] First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC
Background Selpercatinib, a highly selective potent and brain-penetrant RET inhibitor, was
shown to have efficacy in patients with advanced RET fusion–positive non–small-cell lung …
shown to have efficacy in patients with advanced RET fusion–positive non–small-cell lung …
[HTML][HTML] Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
Background RET fusions are oncogenic drivers in 1 to 2% of non–small-cell lung cancers
(NSCLCs). In patients with RET fusion–positive NSCLC, the efficacy and safety of selective …
(NSCLCs). In patients with RET fusion–positive NSCLC, the efficacy and safety of selective …
Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program
O Illini, MJ Hochmair, H Fabikan… - … in medical oncology, 2021 - journals.sagepub.com
Introduction: Rearranged during transfection (RET) gene fusions are rare genetic drivers in
non-small cell lung cancer (NSCLC). Selective RET-inhibitors such as selpercatinib have …
non-small cell lung cancer (NSCLC). Selective RET-inhibitors such as selpercatinib have …
LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancer
M Tsuboi, JW Goldman, YL Wu, ML Johnson… - Future …, 2022 - Taylor & Francis
Selpercatinib, a first-in-class, highly selective and potent central nervous system-active RET
kinase inhibitor demonstrated clinically meaningful activity with manageable toxicity in …
kinase inhibitor demonstrated clinically meaningful activity with manageable toxicity in …
Selpercatinib (LOXO-292) in patients with RET-fusion+ non-small cell lung cancer.
3584 Background: Selpercatinib (LOXO-292) is a highly selective and potent small molecule
RET kinase inhibitor. Here we report an update on the efficacy and safety of selpercatinib in …
RET kinase inhibitor. Here we report an update on the efficacy and safety of selpercatinib in …
相关搜索
- selpercatinib in patients ret fusion
- lung cancer ret fusion
- chemotherapy and pembrolizumab ret fusion
- lung cancer selpercatinib in patients
- chemotherapy and pembrolizumab positive nsclc
- lung cancer ib iiia
- ib iiia adjuvant selpercatinib
- lung cancer updated safety
- positive nsclc ret fusion
- lung cancer access program
- lung cancer retrospective analysis
- lung cancer efficacy of selpercatinib
- lung cancer adjuvant selpercatinib
- lung cancer safety of selpercatinib
- safety with selpercatinib ret fusion
- efficacy of selpercatinib ret fusion